uniQure downgraded after FDA backs sham-controlled trial for Huntington’s therapy

Investing.com Gold reports: uniQure downgraded after FDA backs sham-controlled trial for Huntington’s therapy. This is a premium/paywalled source, so the brief is based on headline and available metadata only.